Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon

Human Pathology

Volumn 43, Issue 10, 2012, Pages 1755-1763

  Streppel, Mirte M ^a,b   Vincent, Audrey ^a   Mukherjee, Radha ^a   Campbell, Nathaniel R ^a   Chen, Shih Hsun ^c   Konstantopoulos, Konstantinos ^c   Goggins, Michael G ^a,d   Van Seuningen, Isabelle ^e,f   Maitra, Anirban ^a   Montgomery, Elizabeth A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Johns Hopkins University   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^f UNIV LILLE   (France)

Author keywords

CA125; Digestive tract adenocarcinoma; MUC16

Indexed keywords

CA 125 ANTIGEN; MUCIN; MUCIN 16; TUMOR MARKER; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY; UPREGULATION;

ADENOCARCINOMA; AGED; BLOTTING, WESTERN; CA-125 ANTIGEN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866514473     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.01.005     Document Type: Article

References (33)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. S. Senapati, P. Sharma, S. Bafna, H.K. Roy, and S.K. Batra The MUC gene family: their role in the diagnosis and prognosis of gastric cancer Histol Histopathol 23 2008 1541 1552
3. S. Bafna, S. Kaur, and S.K. Batra Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells Oncogene 29 2010 2893 2904
4. D.W. Kufe Mucins in cancer: function, prognosis and therapy Nat Rev Cancer 9 2009 874 885
5. N. Jonckheere, and I. Van Seuningen The membrane-bound mucins: from cell signaling to transcriptional regulation and expression in epithelial cancers Biochimie 92 2010 1 11
6. N. Jonckheere, and I. Van Seuningen The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies Crit Rev Oncog 14 2008 177 196
7. B.W. Yin, and K.O. Lloyd Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16 J Biol Chem 276 2001 27371 27375
8. B.W. Yin, A. Dnistrian, and K.O. Lloyd Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene Int J Cancer 98 2002 737 740 (Pubitemid 34225625)
9. J. Hilkens, M.J. Ligtenberg, H.L. Vos, and S.V. Litvinov Cell membrane-associated mucins and their adhesion-modulating property Trends Biochem Sci 17 1992 359 363
10. A. Rump, Y. Morikawa, and M. Tanaka Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion J Biol Chem 279 2004 9190 9198 (Pubitemid 38295982)
11. O. Kaneko, L. Gong, and J. Zhang A binding domain on mesothelin for CA125/MUC16 J Biol Chem 284 2009 3739 3749
12. J.A. Gubbels, J. Belisle, and M. Onda Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors Mol Cancer 5 2006 50
13. J.A. Belisle, S. Horibata, and G.A. Jennifer Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes Mol Cancer 9 2010 118
14. C. Seelenmeyer, S. Wegehingel, J. Lechner, and W. Nickel The cancer antigen CA125 represents a novel counter receptor for galectin-1 J Cell Sci 116 2003 1305 1318 (Pubitemid 36410668)
15. C. Haglund Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA Br J Cancer 54 1986 897 901 (Pubitemid 17204439)
16. T. Yue, I.J. Goldstein, and M.A. Hollingsworth The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays Mol Cell Proteomics 8 2009 1697 1707
17. Y. Haga, K. Sakamoto, and H. Egami Clinical significance of serum CA125 values in patients with cancers of the digestive system Am J Med Sci 292 1986 30 34 (Pubitemid 17057425)
18. Y.H. Zhang, Y. Li, C. Chen, and C.W. Peng Carcinoembryonic antigen level is related to tumor invasion into the serosa of the stomach: study on 166 cases and suggestion for new therapy Hepatogastroenterology 56 2009 1750 1754
19. T. Fujimura, S. Kinami, and I. Ninomiya Diagnostic laparoscopy, serum CA125, and peritoneal metastasis in gastric cancer Endoscopy 34 2002 569 574 (Pubitemid 34712002)
20. B. Fan, and B. Xiong Investigation of serum tumor markers in the diagnosis of gastric cancer Hepatogastroenterology 58 2011 239 245
21. A. Webb, P. Scott-Mackie, and D. Cunningham The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer Eur J Cancer 32A 1996 63 68
22. K.K. Wang, and R.E. Sampliner Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus Am J Gastroenterol 103 2008 788 797 (Pubitemid 351406009)
23. American Gastroenterological Association, S.J. Spechler, P. Sharma, R.F. Souza, J.M. Inadomi, and N.J. Shaheen American Gastroenterological Association medical position statement on the management of Barrett's esophagus Gastroenterology 140 2011 1084 1091
24. C.A. Goodell, J.A. Belisle, and J.A. Gubbels Characterization of the tumor marker muc16 (ca125) expressed by murine ovarian tumor cell lines and identification of a panel of cross-reactive monoclonal antibodies J Ovarian Res 2 2009 8
25. F. Macdonald, R. Downing, and W.H. Allum Expression of CA125 in pancreatic carcinoma and chronic pancreatitis Br J Cancer 58 1988 505 506 (Pubitemid 18267810)
26. T. Einama, H. Kamachi, and H. Nishihara Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma Pancreas 40 2011 1276 1282
27. H.A. Multhaupt, C.P. Arenas-Elliott, and M.J. Warhol Comparison of glycoprotein expression between ovarian and colon adenocarcinomas Arch Pathol Lab Med 123 1999 909 916 (Pubitemid 29480450)
28. J.H. Lagendijk, H. Mullink, P.J. van Diest, G.A. Meijer, and C.J. Meijer Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach J Clin Pathol 52 1999 283 290 (Pubitemid 29161492)
29. R.W. Brown, L.B. Campagna, J.K. Dunn, and P.T. Cagle Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site Am J Clin Pathol 107 1997 12 19 (Pubitemid 27104630)
30. P. Argani, C. Iacobuzio-Donahue, and B. Ryu Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868 (Pubitemid 34044602)
31. S.L. Swierczynski, A. Maitra, and S.C. Abraham Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays Hum Pathol 35 2004 357 366 (Pubitemid 38339611)
32. R. Hassan, Z.G. Laszik, and M. Lerner Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 2005 838 845 (Pubitemid 41740183)
33. H. Alvarez, P.L. Rojas, and K.T. Yong Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy Nanomedicine 4 2008 295 301